Louise Chen
Stock Analyst at Scotiabank
(3.17)
# 1,223
Out of 4,983 analysts
300
Total ratings
46.62%
Success rate
1.14%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $18.10 | +341.99% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.84 | +389.13% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $14.06 | -0.43% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.63 | +636.20% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $19.34 | +184.38% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $59.69 | -7.86% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $3.27 | +358.72% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $54.51 | -8.27% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $6.42 | +133.64% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $12.54 | +35.57% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $41.44 | +68.92% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $12.99 | +284.91% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.41 | +218.81% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $32.30 | +70.28% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.90 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $57.20 | +179.72% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $31.23 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $216.26 | +10.98% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $23.90 | +88.28% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $176.46 | +21.84% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.26 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $81.09 | +91.15% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.18 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $764.71 | +15.73% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.52 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.29 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.60 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.42 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $64.71 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.82 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.79 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.93 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.20 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $575.06 | +60.85% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.06 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.25 | +1,900.00% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.61 | +210.56% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $3.72 | +572.04% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $17.44 | +186.70% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $16.97 | +194.64% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.08 | +362.96% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.31 | +2,841.18% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $1.97 | +85,659,798.48% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $345.19 | -25.26% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $18.68 | -19.70% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.24 | +3,932.26% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.39 | +1,338.85% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.17 | +527.62% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $18.10
Upside: +341.99%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.84
Upside: +389.13%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $14.06
Upside: -0.43%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.63
Upside: +636.20%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.34
Upside: +184.38%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $59.69
Upside: -7.86%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.27
Upside: +358.72%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $54.51
Upside: -8.27%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $6.42
Upside: +133.64%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $12.54
Upside: +35.57%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $41.44
Upside: +68.92%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $12.99
Upside: +284.91%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.41
Upside: +218.81%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $32.30
Upside: +70.28%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.90
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $57.20
Upside: +179.72%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.23
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $216.26
Upside: +10.98%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $23.90
Upside: +88.28%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $176.46
Upside: +21.84%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.26
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $81.09
Upside: +91.15%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.18
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $764.71
Upside: +15.73%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.52
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.29
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.60
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.42
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.71
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.82
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.79
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.93
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.20
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $575.06
Upside: +60.85%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.06
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.25
Upside: +1,900.00%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.61
Upside: +210.56%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $3.72
Upside: +572.04%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $17.44
Upside: +186.70%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $16.97
Upside: +194.64%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.08
Upside: +362.96%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.31
Upside: +2,841.18%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $1.97
Upside: +85,659,798.48%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $345.19
Upside: -25.26%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $18.68
Upside: -19.70%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.24
Upside: +3,932.26%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.39
Upside: +1,338.85%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.17
Upside: +527.62%